Skip to content

Ezetimibe lipid loWering Trial On PreventIon of Atherosclerosis in 75 or older

Ezetimibe lipid loWering Trial On PreventIon of Atherosclerosis in 75 or older - EWTOPIA75

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001988
Enrollment
6000
Registered
2009-05-21
Start date
2009-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyper-LDL-cholesterolemia

Interventions

Sponsors

Japanese Geriatric Society Public Health Research Foundation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) High-risk outpatients with hyper-LDL-cholesterolemia (serum LDL-cholesterol levels>140mg/dL) aged 75 years and older (at the time of written informed consent) of the both sexes (LDL-cholesterol levels are calculated with Friedewald Formula). (2) At least one of the following factors 1. DM 2. Hypertension 3. Low-HDL-cholesterolemia 4. Hypertriglyceridemia 5. Current smoking 6. History of cerebral infarction 7. PAD

Exclusion criteria

Exclusion criteria: (1) Serum TG level> 400 mg/dL (2) History of myocardial infarction (3) History of PCI or CABG (4) Angina pectoris requiring treatment (5) Recent history of stroke(within 6 months) (6) 1. AST>100 IU/L 2. ALT>100 IU/L 3. liver chirosis (7) Serum creatinine level >3.0 mg/dL (8) Cancer (9) Dementia (10) Familial hyperchoresterolemia (11) Atrial fibrillation (12) Allergy to ezetimibe (13) Patients participating in other clinical trials (14) Patients inappropriate for the trial judged by investigators

Design outcomes

Primary

MeasureTime frame
Composite cardiovascular events (1)Cardiac sudden death (2)Fatal myocardial infarction (3)Non-fatal myocardial infarction (4)PCI or CABG (5)Fatal stroke (6)Non-fatal stroke

Secondary

MeasureTime frame
(1) Composite coronary events (cardiac sudden death, fatal myocardial infarction or non-fatal myocardial infarction) Cardiac sudden death Fatal or non-fatal myocardial infarction PCI or CABG Fatal or non-fatal stroke Fatal stroke Non-fatal stroke Fatal or non-fatal cerebral infarction Fatal cerebral infarction Non-fatal cerebral infarction TIA Fatal or non-fatal cerebral hemorrhage Fatal cerebral hemorrhage Non-fatal cerebral hemorrhage CAS or CEA Revascularization for PAD (EVT or bypass operation) Aortic dissection Rupture of aortic aneurysm Operation for aortic aneurysm (2) All-cause death Cardiovascular death (cardiac sudden death, fatal myocardial infarction or fatal stroke) Non-cardiovascular death Death for cancer (3) All-cause hospitalization Hospitalization for cardiovascular causes Hospitalization for non-cardiovascular causes (4) Cancer Femoral neck fracture Dementia MMSE GDS15 ADL (TMIG Index for Competence) Admission to nursing homes (5) Adverse events (6) Cost

Countries

Japan

Contacts

Public ContactYoji Mitadera

EWTOPIA75 investigators EWTOPIA75 office

ewtopia@csp.or.jp0120-750-741

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026